Prelude Therapeutics Inc (PRLD) income statement
PRLDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 8/3055% above fair value
$3.30−0.02 (-0.60%)
Close on Nov 18, 2026Market cap $263.35MP/E –Yield –
Prelude Therapeutics Inc income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- -300.6%
- Net margin
- -269.7%
- Return on equity, FY2025
- -99.5%
Financial strength
- Current ratio
- 4.07
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 69.2%
Valuation
- P/E ratio
- –
- Price to sales
- 11.74
- Price to book
- 1.97
- Dividend yield
- –
See a number that looks wrong?